Here, in this perspective article, we briefly summarize the available evidence on the beneficial effects of mifepristone in Cushing’s syndrome and metabolic syndrome and, propose a feasible mode of action that involves the regulation of mitochondrial function, which could explain mifepristone insulin-sensitizing effects. The gene discussed is INS; the disease is metabolic syndrome.